Akeso's (HKG:9926) ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.
The trial assessed the capabilities of ivonescimab plus chemotherapy against tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.
Shares in the drug company nearly 5% during afternoon trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.